Aquestive Therapeutics, INC Form 4 insider transactions

Aquestive Therapeutics officer Peter E. Boyd sold 10,000 shares of common stock for $7 per share under a Rule 10b5-1 plan.

Daniel Barber, President and CEO of Aquestive Therapeutics, Inc., sold 91,343 shares of common stock for approximately $6.03 per share pursuant to a Rule 10b5-1 trading plan.

Peter E. Boyd, an officer and director of Aquestive Therapeutics, Inc., sold 10,000 shares of common stock at $6.30 per share.

Aquestive Therapeutics' President and CEO, Daniel Barber, sold 400 shares of common stock for $6 per share as part of a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics' Chief Operating Officer, Cassie Jung, executed a pre-planned transaction, exercising stock options and selling common stock.

Aquestive Therapeutics' SVP of IT, HR, & Communications, Peter E. Boyd, sold 15,000 shares of common stock for $5.30 per share under a 10b5-1 plan.

Aquestive Therapeutics' Chief Commercial Officer, Sherry Korczynski, received a grant of 25,000 restricted common shares as part of her compensation.

Aquestive Therapeutics' Chief Medical Officer, Carl N. Kraus, had 10,819 shares withheld for tax obligations related to RSU vesting.

Aquestive Therapeutics, Inc. Director Gregory B. Brown reported the acquisition of 42,000 stock options and disclosed his beneficial ownership of 75,085 shares of common stock.

Aquestive Therapeutics, Inc. Director Julie Krop was granted 42,000 stock options with an exercise price of $3.41, vesting fully on June 11, 2026.

Aquestive Therapeutics, Inc. Director Timothy E. Morris was granted 42,000 stock options with an exercise price of $3.41, vesting fully on June 11, 2026.

Aquestive Therapeutics, Inc. Director Abigail L. Jenkins was granted 42,000 non-qualified stock options with an exercise price of $3.41 per share, vesting fully on June 11, 2026.

Aquestive Therapeutics, Inc. (AQST) Director John Cochran reported the acquisition of 42,000 stock options, aligning his interests with shareholder value.

Aquestive Therapeutics, Inc. director Marco Taglietti was granted 42,000 stock options with an exercise price of $3.41, vesting fully on June 11, 2026.

Aquestive Therapeutics, Inc.'s Senior Vice President of Sales and Marketing, Sherry Korczynski, reported a routine transaction involving the withholding of 2,714 common shares to cover tax obligations related to the vesting of Restricted Stock Units.

Melina Cioffi, SVP of Regulatory Affairs at Aquestive Therapeutics, reports acquiring 20,000 shares of common stock on May 15, 2025.

Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options.

Cassie Jung, Chief Operating Officer of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options.

A. Ernest Toth Jr., CFO of Aquestive Therapeutics, reports acquisition and disposal of common stock and stock options.

Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options.

Sherry Korczynski, SVP of Sales and Marketing at Aquestive Therapeutics, reports acquisition of shares and options, along with disposition of shares to cover tax obligations.

Lori Braender, Chief Legal Officer of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options.

Peter E. Boyd, an executive at Aquestive Therapeutics, reports the acquisition and disposal of common stock and stock options.

Daniel Barber, CEO of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options related to vesting and tax obligations.

Director Douglas K. Bratton reported a transaction involving 40,000 shares of Aquestive Therapeutics common stock, along with details of his indirect holdings through various entities.

Aquestive Therapeutics' Chief Operating Officer, Cassie Jung, reported the sale of 44 shares of common stock and indirect ownership of 2,000 shares through her spouse.

Alexander Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, reports the withholding of shares to cover tax obligations related to vested Restricted Stock Units.

Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, reports disposing of shares to cover tax obligations related to vesting Restricted Stock Units.

Daniel Barber, CEO of Aquestive Therapeutics, amends his Form 4 filing to revise the number of shares withheld for tax obligations related to vested Restricted Stock Units.

Cassie Jung, SVP of Operations at Aquestive Therapeutics, files an amended Form 4 to correct the number of shares withheld for tax obligations related to vesting Restricted Stock Units.